Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in Chinese female patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

NCT04452370

Triple Negative Breast Cancer

UNKNOWN PHASE2

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

NCT03535961

Breast Cancer

COMPLETED PHASE2

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

NCT01589159

Metastatic Breast Cancer

COMPLETED PHASE2

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

NCT07019337

HER2-positive Breast Cancer Metastatic Breast Cancer

NOT_YET_RECRUITING PHASE2

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

NCT04165993

Metastatic Breast Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Current recommended dosage of Etoposide in treating breast cancer is 50 mg/m2 orally once a day for 21 days, repeated every 28 days. With retrospective data review, this study intends to adjust Etoposide dose to 60 mg/m2 daily for 10 days, repeated every 21 days as a cycle, to investigate the effectiveness and safety of Etoposide monotherapy in the treatment of recurrent or metastatic breast cancer in Chinese female patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Etoposide

Etoposide Capsules

Group Type EXPERIMENTAL

Etoposide

Intervention Type DRUG

Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etoposide

Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lastet, VP-16

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-80 years old.
* ECOG status: 0-2.
* Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer.
* No more than three prior chemotherapies, adjuvant chemotherapy excluded.
* Received prior anthracycline, taxane therapy.
* At least 4 weeks from previous chemotherapy.
* Measurable disease of \>=2 cm (\>=1 cm on spiral CT scan).
* Life expectancy of ≥ 3 months.
* Adequate organ functions:

* Hemoglobin ≥10.0 g/dl, Absolute neutrophil count ≥1.5×10\^9/L, Platelet count ≥100×10\^9/L,
* Creatinine clearance ≥60ml/min,
* Bilirubin ≤1.5 times upper limit of normal (ULN); AKP,AST and ALT ≤2.5x ULN(≤5x ULN if due to liver metastases).
* Signed informed consent.
* Menopausal women or received surgical sterilization, women with children potential must not be pregnant or nursing with negative pregnancy test and willing to practice acceptable methods of birth control during the study and 3 months after the study.

Exclusion Criteria

* Pregnancy or lactation.
* Untreated or uncontrolled CNS metastases, or with refractory psychiatric illness.
* Prior treatment with Etoposide.
* Other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer.
* Clinically significant heart diseases (e.g.congestive heart failure, symptomatic coronary disease, uncontrolled cardiac arrhythmia, Myocardial infarction) within the past 12 months.
* Serious uncontrolled concurrent infection or metabolism disorder.
* Concurrent treatment for active peptic ulcer disease or with digestive disorders.
* Prior radiotherapy and major surgery within 3 weeks before screening.
* Less than 4 weeks since prior investigational agents.
* Metastases present in more than one-third whole liver.
* Unable or unwilling to comply with the study protocol.
* Unsuitable to participate in study, that in the opinion of the treating physician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Binghe Xu

Deputy Director of Department of Medical Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Binghe Xu, M.D., Ph.D

Role: PRINCIPAL_INVESTIGATOR

Chinese Academy of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.